Resveratrol for Alzheimer Disease

Resveratrol was safe and well tolerated in patients with mild-to-moderate AD, but effects on biomarkers and clinical significance remain to be clarified.

Resveratrol, a polyphenol with potential antioxidant properties, has been associated with decreasing Alzheimer disease (AD) pathology in animal models. Data are limited in humans. In this randomized, double-blind, placebo-controlled, phase 2 clinical trial, researchers investigated the safety and efficacy of resveratrol in mild-to-moderate AD. Primary outcomes also included AD biomarkers, including plasma and cerebrospinal fluid (CSF) amyloid-beta 40 (Aβ40) and amyloid-beta 42 (Aβ42) levels, CSF tau and phospho-tau 181 levels, and volumetric magnetic resonance imaging (MRI) rates of change in the whole brain, ventricles, hippocampi, and entorhinal cortex.

Participants were randomized to receive resveratrol or placebo for 52 weeks, with follo…

Reviewing Author

Jennifer Rose V. Molano, MD

Disclosures

Grant/Research SupportNational Center for Advancing Translational Science – Cincinnati Center for Clinical and Translational Science and Training

Editorial BoardsBrain & Life

Jennifer Rose V. Molano, MD

Disclosures

Grant/Research SupportNational Center for Advancing Translational Science – Cincinnati Center for Clinical and Translational Science and Training

Editorial BoardsBrain & Life

Resveratrol for Alzheimer Disease

Topics

Reviewing Author